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Abstract
During infection, pathogens utilize surface receptors to gain entry into intracellular compartments. 
Multiple receptor-ligand interactions that lead to pathogen internalization have been identified and 
the importance of multivalent ligand binding as a means to facilitate internalization has emerged. 
The effect of ligand density, however; is less well known. In this study, ligand density was 
examined using poly(DL-lactic-co-glycolic acid) nanoparticles (PLGA NPs). A cyclic peptide, 
cLABL, was used as a targeting moiety as it is a known ligand for intercellular cell adhesion 
molecule-1 (ICAM-1). To modulate the number of reactive sites on the surface of PLGA NPs, 
modified Pluronic® with carboxyl groups and Pluronic® with hydroxyl groups were combined at 
different ratios and the particle properties were examined. Utilizing a surfactant mixture directly 
affected the particle charge and the number of reactive sites for cLABL conjugation. The surface 
density of cLABL peptide increased as the relative amount of reactive Pluronic® was increased. 
Studies using carcinomic human alveolar basal epithelial cells (A549) showed that cLABL density 
may be optimized to improve cellular uptake. These results compliment other studies suggesting 
surface density of the targeting moiety on the NP surface should be considered to enhance the 
effect of ligands employed for cell targeting.
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Introduction
The interaction between leukocyte function associated antigen-1 (LFA-1) present on 
lymphocytes such as T cells and intercellular cell adhesion molecule-1 (ICAM-1) on antigen 
presenting cells (APC) represents an interesting therapeutic target1–3. This interaction is a 
part of T-cell activation through the immunologic synapse, which forms at the interference 
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between T cells and APCs3–6. The expression of ICAM-1, which is a ligand for LFA-1, has 
been investigated in a variety of cells1,7. Different cytokines can up-regulate ICAM-1 on the 
surface of cells2,7–8. Reports have also suggested a link between tumor growth attenuation 
and overexpression of ICAM-1 induced by inflammatory cytokines such as TNF-α1–2,7–8. 
ICAM-1 up-regulation has been observed in many different inflammatory diseases and 
cancers cells such as melanomas, lymphomas, and lung carcinomas, which makes this 
receptor an interesting target for therapeutic delivery1,8.
Peptides derived from binding domains of LFA-1 and ICAM-1 have been developed as 
ligands for the opposing receptors. Cyclo(1,12)-PenITDGEATDSGC (cLABL), a cyclic 
peptide, is derived from I-domain of αL-subunit of LFA-1 integrin. This peptide can inhibit 
homotypic and heterotypic T-cell adhesion to epithelial and endothelial cells by blocking the 
LFA-1/ICAM-1 interaction9. Furthermore, cLABL has been employed as a targeting ligand 
for intracellular delivery2,10. Accordingly, cLABL conjugated to poly(DL-lactic-co-glycolic 
acid) nanoparticles (PLGA NPs) was designed to target anti-cancer drugs to carcinomic 
human alveolar basal epithelial cells, A549, via ICAM-11.
Understanding the ligand-receptor interactions between cells or other biological components 
can be helpful to enhance the efficiency of targeting systems by improving binding avidity 
and cellular uptake. The structure of viruses such as adenovirous type 2 and the surface 
density of their ligands have been studied to surmise the importance of multivalent ligands 
on binding efficiency11. Studies showed that penton-base proteins presented on adenovirus 
type 2 cover the surface of these viruses with regular spacing11. The surface density 
presented by this virus may substantially improve binding avidity to the cell receptors. The 
simulation of the natural structure of viruses based on their ligand density has been utilized 
to engineer targeted clustered ligands11–12. Studies showed that, the optimum distribution of 
ligands on the surface of viruses is a key factor for binding and cellular uptake. Control of 
ligand density on NPs should provide a means to increase receptor binding avidity and 
cellular uptake.
The effect of ligand density (e.g. peptide conjugated to NPs) on binding and cellular uptake 
has not been thoroughly explored. Reports have shown that increasing conjugated ligands on 
particles often increases the cellular uptake13–15. In general, these studies showed that 
ligands must be present on the surface of NPs above a minimum threshold for binding to 
occur16. However, a few studies also showed that dense surface coverage may not offer 
expected improvements in binding and cellular uptake13–16.
In this study, the effect of ligand density on receptor binding and cellular uptake was 
investigated using surface modified PLGA NPs exhibiting conjugated cLABL peptide. To 
control the number of reactive sites for conjugation on the surface of NPs, mixtures of two 
surfactants were used during NP fabrication. Such surface modification provided a 
controllable number of reactive sites on the surface of the NPs for peptide conjugation, 
allowing us to modulate the peptide surface density on the NPs as a means to optimize 
binding and cellular uptake. Binding experiment using A549 cells were utilized to evaluate 
the effect of ligand density on NP binding to the cells.
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Polymers of poly(DL-lactic-co-glycolic acid) (50:50) (PLGA with inherent viscosities of 0.22 
dL/g, (Mw~6.7 kDa; carboxyl terminal group) and 1.05 dl/g (Mw~101 kDa) were purchased 
from LACTEL Absorbable Polymers International (Pelham, AL, USA). Pluronic® F38 
(Mw~4700 Da), Pluronic® F68 (Mw~8400 Da), Pluronic® F108 (Mw~14600 Da), and 
Pluronic® F127 (Mw~12600 Da) were obtained from BASF Corporation (Mount Oliver, NJ, 
USA). 1-ethyl-3-[3-dimethylaminopropyl]carbodiimidehydrochloride (EDC) and N-
hydroxysulfosuccinimide (sulfo-NHS) were purchased from Thermo Scientific (Rockford, 
IL, USA). Coumarin-6 was purchased from Polysciences, Inc. (Warrington, PA, USA). 
Tetrahydrofuran (THF), triethylamine, acetone, diethyl ether, 1X Tris/EDTA buffer solution 
pH 8, sodium hydroxide, and ethyl alcohol were obtained from Fisher Scientific (Fair Lawn, 
NJ, USA). D-mannitol, (dimethylamino)pyridine (DMAP), succinic anhydride, and Triton 
X-100 were purchased from Sigma-Aldrich (St. Louis, MO, USA). Cyclo(1,12)-
PenITDGEATDSGC (cLABL) was synthesized in-house using a reported method1–2. 
Millex™ syringe driven filter unit (MCE 0.45 µm MF) was purchased from Millipor 
Corporation (Bedford, MA, USA). Dialysis membrane (MWCO 100,000) was obtained 
from Spectrum Laboratory Products Inc. (Rancho Dominguez, CA, USA). F-12K medium 
and A549 cell line were purchased from American Type Culture Collection (Manassas, VA, 
USA). Recombinant, human, tumor necrosis factor-α (TNF- α) was obtained from Promega 
(Madison, WI, USA). BCA™ protein assay kit was obtained from Thermo Scientific 
(Rockford, IL, USA). Costar® 3596 and Costar® 3631 were purchased from Corning 
Incorporated (Corning, NY, USA).
Conversion of terminal hydroxyl groups to terminal carboxyl groups on Pluronic®
To conjugate cLABL to Pluronic®, the terminal hydroxyl groups were converted to carboxyl 
groups on Pluronic® F38, F68, F108, and F1271–2,17. First, 12.87 mM of each surfactant 
was dissolved in 10 mL of tetrahydrofuran (THF). Then, 4-dimethylaminopyridine (DMAP, 
24.5 mg), triethylamine (27 µL) and succinic anhydride (200 mg) were added to the solution. 
The mixture was kept on a stirrer for 48 hours at room temperature in a closed bottle. THF 
was then removed using a rotary evaporator (Rotoevaporator-R, Büchi, Switzerland) and the 
product was dissolved in about 15 mL of carbon tetrachloride. Filtration was utilized to 
remove the excess succinic anhydride (0.45 µL cutoff). Each type of Pluronic® with terminal 
carboxyl groups was purified by precipitation using 25 mL diethylether and recrystallized 
with 10 mL ethyl alcohol. Rotary evaporation was performed to remove the solvents after 
precipitation and recrystallization. Finally, the products were kept in a vacuum chamber 
overnight to remove the solvents. Modified Pluronics® were characterized by 1H NMR 
spectroscopy (Bruker AVANCE 400 MHz spectrometer) to confirm the functional group 
conversion. Chloroform-d (CDCl3) was used to dissolve Pluronics® for 1H NMR sample 
preparation.
Preparation of PLGA nanoparticles with a mixture of two surfactants
A solvent displacement method was employed to prepare PLGA NPs1–2. To obtain different 
degrees of reactive sites for peptide conjugation (via terminal Pluronic® carboxyl groups), 
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the following method was employed. Briefly, PLGA (inherent viscosity 0.22 dL/g or 1.05 
dL/g) was dissolved in acetone (15 mg/mL). For nanoparticle labeling, Coumarin-6 was also 
dissolved in acetone (2 mg/mL). The mixture of 1425 µL of PLGA solution, 75 µL 1X Tris/
EDTA buffer solution, and 20 µL Coumarin-6 solution was injected into a 15 mL water 
phase containing 0.1% w/v Pluronic® using a syringe pump at 10 mL/hr while stirring (1000 
rpm). In order to prepare NPs without labeling, a mixture of 1425 µL of PLGA solution and 
75 µL of 1X Tris/EDTA buffer solution was injected into the water phase. Aqueous mixtures 
of surfactants were made by dissolving different types of Pluronic® with different functional 
groups (hydroxyl or carboxyl groups) (0.1 % w/v). To fabricate NPs for cLABL 
conjugation, several surfactant ratios of Pluronic® F108-COOH and Pluronic® F68-OH 
(100:0, 75:25, 50:50, 25:75, and 0:100 ratios (v:v)) were made by combining these 
surfactants before transferring the PLGA solution to the surfactant solution. The PLGA NPs 
spontaneously formed as a result of the rapid diffusion of acetone that occurred when the 
organic solution was injected into the water solution. Stirring was continued for 1.5 hours. 
The excess surfactant was removed by dialysis against a 0.2% D-mannitol aqueous solution.
cLABL peptide conjugation to PLGA nanoparticles
For each conjugation reaction, 1 mL of an aqueous suspension of PLGA NPs (~1.5 mg/mL) 
coated with the different Pluronic® F108-COOH and Pluronic® F68-OH ratios was buffered 
at pH 6.5 using 100 µL 2-(N-morpholino)ethanesulfonic acid (MES, 0.1 mM). NPs 
encapsulating Coumarin-6 and NPs without Coumarin-6 were used to make NPs with 
conjugated cLABL (PLGA NPs+Coumarin-6+cLABL) or unlabeled NPs conjugated with 
cLABL (PLGA NPs+cLABL), respectively (Table 2). The NP suspension was then 
incubated with 150 mM 1-ethyl-3-[3-dimethylaminopropyl]carbodiimidehydrochloride 
(EDC) and 50 mM N-hydroxysulfosuccinimide (sulfo-NHS) for 15 minutes with mild 
agitation1,18–19. Before starting the conjugation process, NP suspensions were washed three 
times with distilled water to remove excess EDC and sulfo-NHS using centrifugation 
(15,000 rpm, 15 min, 4°C) and sonication to aid resuspension of the centrifuged pellet 
(Branson 2510 ultrasonic cleaner, USA). Then, NP suspensions were buffered with 100 µL 
of phosphate buffered saline (PBS). The carboxyl terminal groups of Pluronic® F108-
COOH were activated to conjugate the amino terminus of cLABL peptide. After activation 
of the carboxyl groups of Pluronic® F108-COOH, 100 µL of cLABL aqueous solution (1 
mg/mL) was added to NP suspensions react the N-terminus of cLABL peptide to the 
activated carboxyl group on Pluronic® F108-COOH on the NPs. The conjugation was 
performed overnight at room temperature. After conjugation, NPs were separated from the 
excess peptide using centrifugation (15,000 rpm, 15 min, 4°C) and washed three times with 
distilled water. Then, the particles were dispersed in water by placing the vials in a 
sonication bath (Branson 2510 ultrasonic cleaner, USA) (Figure 1).
Particle size and zeta potential characterization
Particle size and zeta potential were measured using a ZetaPALS dynamic light scattering 
instrument (Brookhaven, USA). A transmission electron microscope (FEI field emission 
transmission electron microscope, Tecnai G2 at 200 kV) was employed for morphological 
characterization. TEM samples were prepared by depositing a drop of NP solution on a 
copper carbon grid and allowing it to dry in a dessicater overnight.
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Evaluation of cLABL peptide surface density using HPLC
The amount of cLABL added to the NP suspension before conjugation and the unconjugated 
recovered peptide after conjugation reaction was quantified by gradient reversed- phase 
HPLC using a Vydac® HPLC column (protein and peptide C18). The HPLC system consists 
of Shimadzu SCL-10A system controller, SIL-10A XL with sample collector (50 µL 
injection volume at 4°C), a SPD-10A UV-Vis detector (220 nm wavelength of detection), 
LC-10AT VP solvent delivery pumps, and a DGU-14A degasser. Data acquisition was 
performed by Shimadzu class VP software (version 4.2). Mobile phase A was acetonitrile/
water (5/95% v/v) with 0.1% trifluoroacetic acid (TFA). Mobile phase B was acetonitrile/
water (90/10% v/v) with 0.1% TFA. Gradient elution was performed at a constant flow of 1 
mL/min, from 100% A to 0% A (corresponding to 0% B to 100% B) for 15 min, maintained 
at 100% B for 3 min, followed by a return to 100% A and subsequent column re-
equilibration for 13 minutes. The peptide density on the surface of NPs was calculated by 
subtracting the amount of recovered peptide after conjugation from the amount of peptide 
added to the NP suspension divided by the total surface area assuming a normal Guassian 
particle size distribution. A standard curve was based on several dilutions of cLABL in 
water and used to calculate the cLABL concentration for each sample. NP suspension 
buffered with MES and PBS without EDC/Sulfo-NHS was used as negative control. The 
cLABL was added to the negative control at the same concentration as normal samples in 
which carboxyl groups on NPs were activated with EDC/Sulfo-NHS.
Nanoparticle binding to ICAM-1 and cellular uptake
Carcinomic human alveolar basal epithelial cells, A549, were cultured in F-12K medium 
containing 10% FBS and 0.1% penicillin-stereptomycin for 48 hours (37°C, 5% CO2). Cell 
density of 8×104 cells/mL was maintained and 100 µL of cell suspension was seeded in each 
well of a Costar® 3596 96-well plate, and incubated for 12 hours. The medium was then 
replaced by fresh medium containing TNF-α (1,000 U/mL) for 48 hours to up-regulate 
ICAM-1 receptor expression7–8. F-12K medium was then used to wash the cells three times 
and the cells were incubated with a fresh serum-free medium containing 0.3 mg/mL of 
labeled cLABL-NPs (NPs encapsulating Coumarin-6). NPs encapsulating Coumarin-6 but 
without conjugated cLABL were used as negative controls. The cells were then incubated 
with NPs for different periods of time (5, 10, 15, 30, and 60 minutes) to evaluate the binding 
and uptake of cLABL-NPs. Cold PBS was used to wash the cells three times after 
incubating cells with NPs and then the cells were lysed with 0.2 M NaOH with 0.5% Triton 
X-1001. A fluorescence plate reader (Spectramax M5; ex: 450 nm, em: 500 nm) was 
employed to quantify fluorescence resulting from NPs incubated with cells1. The measured 
fluorescence intensity was normalized by protein concentration that was evaluated using a 
BCA™ protein assay kit according to the manufacturer’s instructions.
Fluorescence microscopy of cLABL-NPs with A549 cells
To compare the biding and uptake of NPs with different peptide densities, fluorescence 
microscopy was utilized onto evaluate NP interactions with A549 cells. A549 cells (300 µL, 
8×104 cells /mL) were seeded on an 8-well plate. Then, the cells were activated by using 
fresh medium (200 µL) containing 1000 U/mL of TNF-α for 24 hours. Cells were then 
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washed with F-12K medium three times and incubated with labeled cLABL-NPs (0.5 
mg/mL in fresh serum free medium) (100:0, and 50:50 surfactant ratios). Labeled NPs 
without conjugated cLABL were used as a control. Different time points (0, 10, 30, and 60 
minutes) were selected to evaluate NP binding and uptake. After 0, 10, 30, and 60 minutes15 
minutes, cells were washed three times using cold PBS to remove unbound NPs. Finally, the 
cells were fixed using 4% paraformaldehyde. Fluorescence micrographs were acquired using 
the FITC filter set of a Nikon Eclipse 80i microscope equipped for epifluorescence. 
Micrographs were captured using an Orca ER camera (Hamamatsu, Inc., Bridgewater, NJ) 
and analyzed by Metamorph, version 6.2 (Universal Imaging Corp., West Chester, PA).
Statistical analysis
Statistical analysis was performed by analysis variance (one-way ANOVA). To assess the 
significance of differences, Newman-Keuls was used as a post hoc test. The t-test was 
utilized to compare the significance of the difference between the means of two groups. A 
value of p<0.05 was accepted as significant in all cases.
Results and discussion
Conversion of terminal hydroxyl groups to terminal carboxyl groups on Pluronic®
In order to utilize Pluronic® for conjugation to the terminal amine of the cLABL peptide, the 
hydroxyl groups of Pluronic® were converted to carboxyl groups. Pluronics® with carboxyl 
groups were prepared by the reaction of Pluronic® with succinic anhydride. The reaction 
was performed in 10 mL THF. To confirm this conversion, 1H NMR spectra before and after 
conversion were compared. After conversion, the signal corresponding to the hydroxyl 
group (δ=4.3) disappeared whereas peaks due to the protons adjacent to the succinic moiety 
and the proton of the carboxylic acid could be detected at δ=4.1 ppm and δ = 11.95 ppm. 1H 
NMR validated functional group conversion (Supplementary figure 1)1,17.
Effect of Pluronic® structure on particle size
PLGA of two different inherent viscosities (0.22 dL/g and 1.05 dL/g) were used to evaluate 
the effects of different types of Pluronic® on particle size. Pluronic®, a triblock copolymer 
composed of a central hydrophobic chain of poly(propylene oxide) flanked by two 
hydrophilic chains of poly(ethylene oxide) was used as a surfactant in the processes of NP 
fabrication and surface functionalization20–22. The central hydrophobic part of Pluronic®, 
poly(propylene oxide), can embed within PLGA during NP fabrication, linking Pluronic® to 
the NP1. The hydrophobic chain must be long enough to hold Pluronic® to the surface of 
PLGA NPs. These polymeric chains also provide a hydrophilic shell for NPs, which can 
stabilize the colloid and limit opsonization, potentially extending the in vivo half-life to 
prolong the therapeutic effect23–24.
Polymeric chains extending from the NP surface can also make targeting moieties more 
accessible to cellular receptors. Poly(ethylene glycol) (PEG) has been used in many studies 
to conjugate ligands to the surface of polymeric NPs and liposomes3,14–15,25–27. These 
studies have shown binding to cellular receptors and uptake by the cell are dependent on the 
length of the PEG utilized3,25. Targeting moieties are usually conjugated to an intermediate 
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length polymeric chain (~2–15kDa) to make a targeted NP system18–19,28–29. According to 
some studies, PEG with higher molecular weight (~10–15 kDa) may improve ligand 
accessibility to the receptor3,25,30, but the optimum reported length has varied depending on 
the NP system. To attach targeting moieties to the polymer chains, polymer chains must 
have suitable reactive sites22,31. In this study, poly(ethylene oxide) chains on Pluronic® have 
terminal hydroxyl groups that can be converted to terminal carboxyl groups prior to NP 
formation to enable facile peptide conjugation1,17.
Pluronic® has a variety of structures with differing molecular weight and number of 
repeating units in the blocks20–21. Unmodified Pluronic® F38, F68, F108, and F127 (Table 
1) were selected since each type provides a different coating thickness (e.g. hydrophilic 
block length) to NPs, and also provides different ligand accessibility to the receptors21. This 
study showed that increasing PLGA inherent viscosity reduced the particle size by about 
50% in each formulation. The molecular weight of surfactants resulted in differences in the 
size of NPs based on the type of Pluronic®. The result suggested that increasing surfactant 
molecular weight caused slight increase in particle size (Figure 2). Pluronic® F38 was not 
used in the final formulation for peptide conjugation due to concerns that it may detach from 
the particle surface as a result of the small hydrophobic block. Instead, Pluronic® F68 and 
Pluronic® F108 were selected to design a formulation for peptide conjugation.
Preparation of PLGA nanoparticles using a mixture of two Pluronic® surfactants
NPs fabricated using unmodified Pluronic® (terminal hydroxyl groups) and carboxyl- 
modified Pluronic® were compared to determine the effect of terminal group conversion on 
PLGA particle size. For all four types of Pluronic®s employed in the preparation process, no 
significant change in particle size was observed as a result of converting the termini (Figure 
3). This effect was observed in all four formulations independent of the molecular weight of 
surfactant.
To control the number of reactive sites (carboxyl groups) on the NP surface for peptide 
conjugation, NPs were prepared using a mixture of unmodified Pluronic® with hydroxyl 
terminal groups and low molecular weight (Pluronic® F68-OH) and modified Pluronic® 
with carboxyl terminal groups and high molecular weight (Pluronic® F108-COOH). This 
mixture was chosen to keep particle size smaller than 200 nm and increase ligand 
accessibility as a result of the longer hydrophilic block on the reactive Pluronic®. Particles 
smaller than 200 nm were desired since this size has been reported to evade clearance by 
macrophages23.
Unmodified Pluronic® F68 (Pluronic® F68-OH) and modified Pluronic® F108 (Pluronic® 
F108-COOH) were utilized to make a 1% w/v aqueous solution for preparing PLGA NPs. 
The ratios of Pluronic® F108-COOH and F68-OH were 100:0, 80:20, 60:40, 40:60, 20:80, 
and 0:100 (v:v). PLGAs with two different inherent viscosities were again studied for each 
surfactant ratio (0.22 dL/g and 1.05 dL/g). Comparing this result with Figure 2 shows that 
increasing the PLGA molecular weight decreased PLGA particle size approximately 1.5-
fold for each sample; moreover, an increase in the relative amount of Pluronic® F68-OH 
decreased particle size slightly (Figure 4).
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Reducing the amount of Pluronic® F108-COOH used to prepare surfactant mixture reduces 
the number of reactive sites on PLGA NPs for peptide conjugation. The amount of peptide 
conjugated to the surface of NPs was, therefore, modulated by controlling the number of 
carboxyl groups (reactive sites) on the surface of NPs (i.e. changing the surfactant ratio). 
Changes in the relative amount of Pluronic® F108-COOH on the NP surface were supported 
by changes in the zeta potential of samples (Figure 5). Terminal carboxyl groups carry more 
negative charge at neutral pH than hydroxyl groups, so zeta potential should become more 
negative as the number of carboxyl groups increases. Reducing the amount of Pluronic® 
F108-COOH in the formulation tended to increase particle zeta potential (Figure 5). The 
relative increase in zeta potential by reducing carboxyl groups on the surface of NPs was 
approximately the same for different types of PLGA.
Effect of cLABL peptide conjugation on particle size and charge
cLABL was conjugated to NPs by reacting the amine terminus (N-terminus) of the peptide 
to carboxyl groups on the NP surface. NPs for peptide conjugation were prepared using the 
ratios of Pluronic® F108-COOH and F68-OH 100:0, 75:25, 50:50, 25:75, and 0:100 (v:v). 
PLGA with an inherent viscosity of 1.05 dL/g was used to achieve the small particle size 
observed in preliminary studies.
The conjugation reaction increased the particle size in all of the samples (Figure 6A). The 
size increase was slightly higher for NPs that had 100% Pluronic® F108-COOH. A very 
small increase in particle hydrodynamic radius may be attributed to the attachment of 
cLABL with the reported molecular weight of 1,170 Da32. However, the sample with 100% 
unreactive Pluronic® F68-OH had no reactive sites, and the particle size also increased after 
conjugation. A significant cause of the size increase may be the activation procedure, which 
uses a hydrophobic intermediate. It is more likely that the purification process for NPs, 
which used centrifugation and resuspension cycles, caused increasing particle size. This 
particle size increase was also observed in the negative control after the conjugation reaction 
(104±1.5 nm), even though this simulated reaction did not link the peptide to the NPs. The 
negative control was NPs with 100:0 surfactant ratio incubated with cLABL after incubation 
with EDC/Sulfo-NHS. Transmission electron micrographs of PLGA NPs (50:50 ratio of 
Pluronic® F108-COOH and Pluronic® F68-OH) from NPs before and after conjugation 
suggested particle size increased after conjugation. This result supported the dynamic light 
scattering data for particle size increase after conjugation.The images taken after 
conjugation suggested particle aggregation as a probable source of the particle size increase 
(Figure 6B, C). Conjugation of the cLABL peptide also increased the charge of NPs (Figure 
7). The relative charge increase was similar for all of the formulations. Since increase in 
charge occurred for all ratios (even 0:100) without apparent relation to the amount of 
cLABL conjugated to the particle, the conjugation process using EDC/ Sulfo –NHS might 
be the reason for this increase. Zeta potential for NPs with 100:0 surfactant ratio incubated 
with cLABL after incubation with EDC/Sulfo-NHS was unchanged (-16.4±1.2 mV) 
compared to the zeta potential of NPs with 100:0 surfactant ratio before conjugation 
(−16.98±0.61 mV) (Table 2).
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Calculating cLABL peptide density on the surface of nanoparticles
Reversed phase HPLC was used to determine the efficiency of the coupling reaction 
between the amino group of cLABL and the carboxyl group of Pluronic® F108-COOH. 
Unreacted peptide was collected, quantified and used to calculate the amount of peptide 
conjugated to the NPs. Blank NPs and empty vials were used as controls to ensure that 
peptide was not being adsorbed to surfaces non-specifically. The peptide density on the 
surface of NPs was calculated based on the total NP surface area, assuming a normal 
Guassian particle size distribution (Figure 8). Peptide density was calculated for all five 
samples that were prepared using different surfactant mixture ratios and using PLGA with 
inherent viscosity of 1.05 dL/g. The calculation showed a significantly higher density of 
cLABL conjugated to the sample with 100% Pluronic® F108-COOH in the formulation. 
Reducing reactive sites by reducing the Pluronic® F108-COOH and increasing the 
Pluronic® F68-OH correspondingly decreased peptide density on the surface of NPs (Figure 
8). Although no carboxyl group was available on NPs with the 0:100 surfactant ratios, a 
small amount of cLABL was found, which may be the result of a small amount of peptide 
adsorption on the surface of NPs.
Nanoparticle binding to ICAM-1 and cellular uptake
NP binding to ICAM-1 and cellular uptake was studied using cLABL-NPs and the A549 cell 
line. PLGA NPs encapsulating coumarin-6 were prepared using analogous surfactant 
mixture ratios to yield an incrementally increasing peptide density on the surface of PLGA 
NPs (Table 2). Results from this bioassay suggested that peptide density could be optimized 
for cellular uptake. Over the time course studied, maximum uptake was observed for the 
PLGA NPs when the surfactant ratios of 50:50 or 25:75 were used (Group A). Interestingly, 
the minimum uptake for PLGA NPs occurred with the surfactant ratio of 100: 0 and 75:25 
(Group B) where the maximum peptide density was observed (Figures 9). High peptide 
density is assumed to increase NP binding to cell receptors; however, it seems that the 
density of the peptide on the surface of NPs must be at an optimum level to facilitate binding 
to the receptors16. In this case, the suspected optimum may be about 2–4 pmol/cm2. NPs 
with the surfactant ratio of 0:100 behaved in the same manner as control NPs (Group C). In 
each group, two samples with similar peptide density exhibited similar binding behavior. 
Although NPs with the surfactant ratio of 0:100 contained 100% Pluronic® F68-OH 
incubated with EDC/sulfo-NHS, the results confirmed that conjugation likely did not occur. 
A small amount of cLABL was observed for these NPs, but again this amount was probably 
adsorbed non-specifically.
Fluorescence microscopy of cLABL-NPs with A549 cells
After incubation of labeled NPs with cells for different periods of times, fluorescence 
micrographs were acquired. Labeled NPs without cLABL conjugation were utilized as a 
negative control. Samples with 50:50 and 100:0 ratios were also employed to evaluate the 
effect of peptide density on cell binding and uptake. The NPs encapsulated Caumarin-6 and 
were readily detected with the fluorescence microscope. The micrographs for the negative 
control showed that localization of NPs to the cells was much less than NPs conjugated with 
cLABL. NPs with a 50:50 surfactant ratio also showed the highest localization of NPs 
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around the cells during incubation. Over time, more green color was evident in the images of 
cells and this increase seemed to be maximal in the NPs with the 50:50 surfactant ratio.
The reason for improved receptor binding at moderate ligand density may be due to the 
behavior of receptors during the binding process. ICAM-1 is a transmembrane receptor with 
a molecular weight of 80–114 kDa that is connected to the cytoskeleton and is able to move 
laterally in the lipid membrane33. ICAM-1 mobility on the cell surface leads to a 
phenomenon called “clustering” during ligand binding34. The size of ICAM-1 and the steric 
hindrance effect are two significant factors in receptor clustering during ligand binding to 
ICAM-1, dictating that the receptors stay at an optimum distance from each other35–36. The 
density of ligands on the surface of NPs may perturb optimal clustering. At one extreme, the 
binding affinity may not be sufficient, thus, requiring an increase in ligand density. On the 
other hand, lowering the ligand density to a level that can facilitate clustering without steric 
hindrance may also result in an increase in receptor binding16. The previous simulations of 
virus structure suggest an optimum ligand density on targeting systems can be helpful to 
increase the avidity of receptor binding and cellular uptake11. As a result, ligand spacing on 
engineered targeted nanoparticle systems will be a design consideration in the future.
In this study, a NP system was used to evaluate the effect of ligand density when targeting 
(ICAM-1). Previous studies have demonstrated that cLABL-NPs can be used to target 
ICAM-1 overexpressed on pertinent endothelial and epithelial cell lines1–2. The targeting of 
cLABL-NPs was improved by varying the amount of conjugated cLABL peptide using a 
technique to control the number of reactive sites on the surface of PLGA NPs. After 
characterizing the effect of process parameters on particle size and zeta potential, methods 
were identified to produce small particles with a controlled reactive site density for peptide 
conjugation. Increasing the number of reactive sites directly increased the cLABL peptide 
density on NPs. A cell-based assay and fluorescence imaging showed that decreasing 
surface density to an optimum level enhanced the interaction of cLABL on PLGA NPs with 
ICAM-1 on A549. Results suggested that ICAM-1-targeted PLGA NPs with an optimum 
ligand surface density may be preferred for therapeutic and diagnostic purposes; thus, 
compelling further research on ligand density effects. Data also showed that the ligand 
density proved to be a key factor in defining receptor binding and that decreasing ligand 
surface density on NPs can actually improve binding and cellular uptake of cLABL-NPs into 
A549 cells.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table1
Summary of the different types of Pluronic® used to make PLGA nanoparticles19,20.
Pluronic® Repeats (A-B-A)* Approximate Mw HLB** Coating Layer
(Å)
F38 46-16-46 5000 30.5 58
F68 75-30-75 8350 29 76
F108 128-54-128 14000 27 154
F127 98-67-98 11500 22 119
*
A is the units of poly(ethylene oxide) and B is the units of poly(propylene oxide) in Pluronic structure
**
HLB: Hydrophilic lipohilic balance of the surfactant
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